Reservoir Neuroscience

Executive Summary

Reservoir Neuroscience is a privately held biotechnology company headquartered in Cambridge, Massachusetts, founded in 2020 with a mission to develop first-in-class small molecule therapeutics that target neuroinflammation and restore blood-brain barrier integrity for the treatment of neurodegenerative diseases. The company's platform addresses a fundamental pathology shared across multiple central nervous system disorders, positioning it to potentially modify disease progression rather than merely alleviate symptoms. By focusing on the blood-brain barrier and neuroinflammation, Reservoir aims to tackle the underlying drivers of neurodegeneration, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The approach leverages proprietary small molecules designed to cross the blood-brain barrier and modulate inflammatory pathways, which could offer advantages over larger biologic therapies in terms of dosing, delivery, and patient compliance. As a preclinical-stage company, Reservoir Neuroscience has yet to disclose a specific lead candidate or clinical timeline, but its science has attracted interest from the neurodegenerative disease community. The company's ability to secure additional financing, advance a pipeline candidate into the clinic, or forge strategic partnerships will be critical to its near-term trajectory. Given the significant unmet need in neurodegenerative diseases and the novelty of the blood-brain barrier healing approach, Reservoir represents a high-risk, high-reward opportunity. Early validation through preclinical data or licensing deals could substantially de-risk the platform and support a valuation inflection.

Upcoming Catalysts (preview)

• Q3 2026Series B Financing Round70% success
• Q4 2026Lead Candidate Nomination and IND-Enabling Studies60% success
• Q2 2027First Patient Dosed in Phase 1 Trial40% success